Akili Says EndeavorOTC Is The Only FDA-Authorized Digital Therapeutic For ADHD Available Without A Prescription
Portfolio Pulse from Benzinga Newsdesk
Akili announces that EndeavorOTC is the only FDA-authorized digital therapeutic for ADHD available without a prescription. This product aims to improve attention function in individuals with ADHD through a video game experience.
June 18, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akili's EndeavorOTC has received FDA authorization, making it the only digital therapeutic for ADHD available without a prescription. This could boost Akili's market position and revenue.
The FDA authorization of EndeavorOTC as the only non-prescription digital therapeutic for ADHD is a significant milestone for Akili. This approval could lead to increased adoption and sales, positively impacting the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100